Results from the Phase III SUNMO trial show that the Lunsumio and Polivy combination achieved statistically significant ...

Roche has demonstrated the power of combining two of oncology’s hottest modalities—bispecifics and antibody-drug conjugates ...

Early results from the Phase I/II NXTAGE trial show that NXT007 may achieve hemostatic normalization in patients with ...

Roche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial for those ...

Shares of Roche drew increased retail attention Monday after the Swiss drugmaker said it would move its investigational ...

The pharma group has presented phase 1/2 results with new candidate NXT007 at the International Society on Thrombosis and ...

MAIA Biotechnology Inc., a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer ...

Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.

Cairo – Roche Diagnostics Egypt has signed a Memorandum of Understanding (MoU) with the Egyptian Authority for Unified ...

Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...